The insulin-like growth factor-I receptor (IGF-IR) is involved in tumorigenesis. The aim of the present study was to investigate whether the IGF-IR is a physiological target for p53 in osteosarcoma cells. The p53-induced regulation of IGF-IR levels was studied in a tetracycline-regulated expression system. When expressed in Saos-2, osteosarcoma cells that lack p53, wild-type p53 decreased, whereas mutated p53 increased IGF-IR expression, and IGF-I-induced tyrosine phosphorylation of the IGF-IR. Similarly, wild-type p53 decreased IGF-I-induced tyrosine phosphorylation of IRS-1. A functional and physical interaction between p53 and Sp1, in the regulation of the IGF-R, was studied in osteosarcoma cells. Expression of p53 decreased IGF-IR promoter activity, whereas no effect on promoter activity was seen by Sp1 expressed alone. However, Sp1 counteracted the inhibitory effect of p53 on IGF-IR promoter activity in a dosedependent manner. Furthermore, wild-type and mutated p53 were coimmunoprecipitated with Sp1, indicating a physical interaction between p53 and Sp1.
T HE insulin-like growth factor-I receptor (IGF-IR) belongs to a family of transmembrane tyrosine kinase receptors. Binding of the ligand to the receptor results in receptor autophosphorylation on intracellular tyrosine residues and activation of the receptor's intrinsic tyrosine kinase (1) . After autophosphorylation, the activated IGF-IR phosphorylates IRS-1, which is its major tyrosine-containing substrate. IRS-1 is considered to be a docking protein that can bring together, and thereby regulate, the activity of certain SH2 domain-containing proteins (1) .
Several important pieces of evidence have been presented indicating that the IGF-IR is involved in tumorigenesis: 1) the IGF-IR is overexpressed in many tumors and cancer cell lines (2); 2) cells lacking the IGF-IR cannot be transformed by SV 40 large T antigen, Ha-ras, v-src, Raf, and bovine papilloma virus (3) (4) (5) ; 3) addition of IGF-I prevents apoptosis (6 -8); 4) a reduction in IGF-IR function induces apoptosis in tumor cells (9 -11) ; and 5) overexpression of the IGF-IR protects cells from apoptosis (10, 12) . The molecular mechanism(s) for these tumorigenic effects of the IGF-IR is currently under investigation.
The IGF-IR gene promoter has been previously characterized as lacking TATA or CAAT elements (13) (14) (15) (16) . Transcription is initiated from a single start site within an initiator motif, which directs accurate transcription, in the absence of a TATA-box (17) . Like many TATA-less promoters, the proximal 5'-flanking region of the IGF-IR gene is highly GC rich, and it contains multiple Sp1 and early growth response consensus-binding sequences in both the 5Ј-flanking region and the 5Ј-untranslated region (5Ј-UTR (13)). We have demonstrated earlier that Sp1 increases IGF-IR promoter activity by acting both on GC boxes in the 5Ј-flanking region of the promoter and on one homopurine/homopyrimidine motif (CT element) in the 5Ј-UTR (18) . Sp1 is a member of a multigene family of zinc-finger transcription factors. It activates transcription in mammalian cells, primarily via interaction with GC box elements. Because no common regulatory features have been identified among the promoters bearing actual or putative Sp1 binding sites, it has been suggested that Sp1 provides a basal level of transcription that is subsequently modulated by its interaction with other regulatory factors (19) . It has been demonstrated earlier, in different cell-lines, that Sp1 and p53 interact in the regulation of different promoters (19) .
p53 is believed to be involved in the etiology of many human tumors, and mutations of the p53 gene are the most frequent mutations in human cancers (20, 21) . The p53 protein is a transcription factor that can bind specifically to DNA sequences in various promoters and stimulate their transcriptional activity (22, 23) . It also can function as a transcriptional repressor of many growth-regulated genes (24, 25) . We have recently demonstrated that wild-type p53 expression vectors suppress IGF-IR promoter activity in a dosedependent manner (26) . This effect of p53 is mediated at the level of transcription, and it involves interaction with TBP, the TATA box-binding component of TFIID. p53 precludes binding of TBP to the promoter region and, as a result, TBP is no longer able to assemble a functional transcription initiation complex. On the other hand, mutant forms of p53 stimulated the activity of the IGF-IR promoter (26) .
The aim of the present study was to investigate whether the IGF-IR is a physiological target for p53 in osteogenic tumors. Therefore, we studied whether p53 regulates IGF-IR expression and function in an osteosarcoma cell line lacking endogenous p53. Furthermore, a possible interaction between p53 and Sp1 in the regulation of the IGF-IR promoter in these cells was studied.
Materials and Methods

Tetracycline-regulated expression of p53 in osteogenic sarcoma-derived cells
Saos-2 cells were obtained from the American Type Culture Collection (Rockville, MD). Saos-2 is a human osteogenic sarcoma-derived cell line in which both p53 alleles are deleted (27) . A tetracycline-regulated clone, Saos-2-D4H, was developed as described earlier (28) . Saos-2-D4H cells were grown in DMEM supplemented with 10% FBS. These cells do not express p53 in the presence of tetracycline (2 g/ml). Removal of tetracycline from the cell culture medium results in expression of p53. This p53 expression was dependent on the batch of FCS used, probably depending on whether the serum donors were tetracycline treated or not. Several serum batches were screened; and, to obtain maximal p53 expression in the absence of tetracycline, a serum batch from Upstate Biotechnology Incorporated (Lake Placid, NY, catalog 10 -103, batch 13229) was used in all experiments. The Saos-2-D4H cells express a temperature-sensitive form of p53 [p53V143A mutant; (28) ]. We have demonstrated earlier that temperature-reactivated p53V143A protein efficiently activates endogenous p53 target genes (28) . No p53 is expressed in the presence of tetracycline at 30 C and 37 C, whereas wildtype p53 is expressed (in the absence of tetracycline) at 30 C and a mutant form of p53 is expressed (in the absence of tetracycline) at 37 C.
Cell culture, plasmids, and DNA transfection in transient transfection experiments
Saos-2 cells were grown in DMEM supplemented with 10% FBS. Drosophila Schneider cells were kindly provided by Carl Wu (National Cancer Institute, Bethesda, MD). Schneider cells, which lack endogenous Sp1, were cultured in HyQ-CCM3 serum-free medium (Hyclone Laboratories, Inc, Logan UT).
The effect of Sp1 and/or p53 on IGF-IR promoter activity was studied by transient transfection assays of different expression vectors together with a fragment of the IGF-IR promoter (Ϫ476/ϩ640) fused to a firefly luciferase reporter gene [p0LUC; (18) 3 H is a mutant p53 in which an Arg residue at position 273 is mutated to His. Sp1, inserted into an alcohol dehydrogenase driven plasmid (pADHSp1), also was used as expression vector in transient transfection of Schneider cells.
Saos-2 cells were transfected by the calcium phosphate method using a kit from 5 Prime-3 Prime, Inc. (Boulder, CO); each 60-mm dish received 4 g of reporter plasmid and 1.1 g of expression vectors. Schneider cells were transfected by using the lipofectin method (Lipofectin Reagent, Gibco BRL, Life Technologies, Inc., Gaithersburg, MD); each 60-mm dish received 2 g of reporter plasmid and 1.5 g of expression vectors. Cells were harvested 48 h (Saos-2) or 60 h (Schneider cells) after transfection, and luciferase activities were measured as described earlier (16) . In preliminary experiments, cells were cotransfected with a CMV-␤ gal vector (␤-gal, ␤-galactosidase), but because expression from the CMVpromoter was found to be affected by p53, subsequent experiments were normalized to total protein, which was measured using the BradfordLowry reaction (Bio-Rad, Hercules, CA). In pilot studies of the effect of p53 and/or Sp1 on IGF-IR promoter activity in Saos-2 cells, normalization for transfection efficiency was performed using a RAS-␤-gal plasmid (30) , kindly provided by Ronald Evans (The Salk Institute, San Diego, CA). The levels of ␤-gal generated by this plasmid were not affected by p53, and the results obtained were essentially the same as those obtained using protein normalization.
Immunoprecipitations
Cells were washed twice with ice-cold PBS and harvested in a lysis buffer containing 50 mm NaCl, 4 mm sodium pyrophosphate, 200 mm EDTA, 10 mm NaF, 1 mm phenylmethylsulfonyl fluoride, 2 g/ml aprotonin, and 1% Triton X-100. Lysates were incubated for 1 h at 4 C, then centrifuged at 10,000 ϫ g for 30 min at 4 C to remove Tritoninsoluble material. Protein content of the lysates was determined by the Bio-Rad method. Protein (150 g) from each dish was immunoprecipitated overnight at 4 C with a primary antibody (Sp1, sc-59-G, 1:1000, Santa Cruz Biotechnology, Inc., Santa Cruz, CA; or IGF-IR, sc-713, 1:1000, Santa Cruz Biotechnology), followed by adsorption to 50 l of 10% protein A-sepharose beads (for IGF-IR; Pharmacia Biotech, Inc., Piscataway, NJ or protein G-sepharose beads (for Sp1; GammaBindG Sepharose, Pharmacia) for 5 h at 4 C. Immunoprecipitates were washed 3 times with ice-cold immunoprecipitation buffer containing 10 mm Tris (pH 7.4), 150 mm NaCl, 0.2 mm sodium orthovanadate, 1 mm EDTA, 1 mm EGTA, 0.2 mm phenylmethylsulfonyl fluoride, 1% Triton X-100, and 0.5% Nonidet P-40. The entire immunoprecipitated samples were then boiled for 4 min in sample buffer containing 50 mm Tris (pH 6.7), 2% SDS, 2% ␤-mercaptoethanol, and bromphenol blue as a marker. Samples were then run on 7.5% SDS-PAGE gels and transferred to nitrocellulose membranes using standard electrophoresis and electroblotting procedures.
Preparation of nuclear extracts
Nuclear extracts were prepared as described by Andrews and Faller (19, 31) . Cells were washed in cold PBS, and the cell pellet was then suspended in 10 mm HEPES-KOH (pH 7,9), 1.5 mm MgCl 2 , 10 mm KCl, 0,5 mm DTT, and 0.2 mm phenylmethylsulfonyl fluoride; kept on ice for 10 min; mixed on a vortex mixer for 10 sec; and centrifuged for 10 sec at 14,000 ϫ g. The pellet was resuspended in 20 mm HEPES-KOH (pH 7.9), 25% glycerol, 420 mm NaCl, 1.5 mm MgCl 2 , 0.2 mm EDTA, 0.5 mm dithiothreitol, and 0.2 mm phenylmethylsulfonyl fluoride; incubated on ice for 20 min; and centrifuged for 2 min at 14,000 ϫ g. The supernatant was divided into aliquots and stored at Ϫ70 C. Protein determinations and immunoprecipitations were then performed as described above.
Immunoblotting
Nitrocellulose membranes were blocked with either 3% insulin-free BSA (for phosphotyrosine blotting) or 3% nonfat dry milk in a PBST buffer containing 10 mm sodium phosphate (pH 7.2), 140 mm NaCl, and 0.1% Tween 20. Blots were then immunolabeled overnight at 4 C for phosphotyrosine (05-321, 1:1000, Upstate Biotechnology, Incorporated), IRS-1 (06 -248, 1:1000, Upstate Biotechnology, Incorporated), IGF-IR (sc-713, 1:1000 Santa Cruz Biotechnology), p53 (DO-1, sc-126, 1:000, Santa Cruz Biotechnology). After washing in PBST, the filters were incubated with HRP-conjugated secondary antibodies for 1 h at 4 C, followed by extensive washes in PBST plus 0.1% Triton X-100. Proteins were detected using chemiluminescence (ECL, Amersham, Arlington Heights, IL) according to the manufacture's conditions. Some blots were stripped and reprobed with a different antibody. Blots were stripped by incubation for 1 h at 50 C in a solution containing 62.5 mm Tris-HCl (pH 6.7), 2% SDS, and 0,7% ␤-mercaptoethanol. Blots were then washed for 1 h in several changes of PBST at room temperature and probed with ECL to confirm that antibodies had been completely removed. Blots were then reblocked and immunolabeled as described above.
IGF-I binding assay
Binding to IGF-binding proteins was excluded by using an IGF-I analog, des(1-3)IGF-I, which binds exclusively to the IGF-IR. To determine the level of IGF-IR expression, cells (ϳ200,000) on 12-well plates were washed with PBS and incubated with 1 ml ligand-binding buffer (100 mm HEPES, pH 7.9, 120 mm NaCl, 5 mm KCl, 1.2 mm MgCl 2 , 1 mm EDTA, and 5 mg/ml BSA) containing 50,000 cpm of 125 I-des(1-3)IGF-I and different concentrations of cold ligand for 4 h at 4 C. After washing three times with PBS, cells were lysed at 37 C for 1 h using 0.4 ml of 0.2 N NaOH; and the total radioactivity, as absorbed to a filter, was counted by a ␥ counter (Gamma Trac, Tm Analytic, Elk Grove Village, IL). Cell numbers were determined for wells treated simultaneously with the experimental wells. Data representing specific binding were analyzed according to the method of Scatchard (32) .
Statistical analysis
Values are given as means Ϯ sem. The statistical significance of differences between means were calculated by ANOVA, followed by Student-Neuman-Keul's multiple range test.
Results
Wild-type p53 decreases, whereas mutated p53 increases, IGF-IR levels
p53-induced regulation of IGF-IR levels was studied in a tetracycline-regulated expression system. A Saos-2 clone (Saos-2-DH4 cells), expressing a temperature-sensitive p53 protein, was used. The parental cell line is null for p53. Saos-2-DH4 cells do not express p53 in the presence of tetracycline. However, 5 days in the absence of tetracycline resulted in a high level of expression of both wild-type p53 at its permissive temperature (30 C) and a mutant p53 at 37 C (Fig. 1) . To avoid temperature-induced effects on IGF-IR expression and IGF-I responsiveness, the effects of p53-induction were always related to control cultures kept at the same temperature as the p53-induced cultures (30 C for wildtype p53 and 37 C for mutated p53). Western immunoblots, using an antibody specific for the IGF-IR, demonstrated that expression of wild-type p53 for 5 days decreased (69 Ϯ 8% of controls at 30 C), whereas mutated p53 increased (128 Ϯ 3% of controls at 37 C), IGF-IR expression, compared with cells not expressing p53 (Fig. 2, A and B) . Thus, cells expressing mutated p53 expressed 85% more IGF-IR protein, compared with cells expressing wild-type p53 (Fig. 2B) .
The effect of p53 on IGF-IR levels, as measured using Western blot, was confirmed using IGF-I binding assays. Because we have previously shown that p53 regulates IGFBP-3 expression, 125 I-des(1-3)IGF-I was used, to avoid interaction with IGFBPs in the binding assay. Saos-2-DH4 cells with no p53 expression have approximately 43,000 receptors/cell (Fig. 3) . There was no significant difference in the number of IGF-IRs per cell in cells with no p53 expressed (cultured at 30 C), compared with those cultured at 37 C. Expression of wild-type p53 decreased IGF-IRs to 32,000/ cell, whereas cells expressing mutated p53 expressed 55,000 receptors/cell. Thus, cells expressing mutated p53 had 72% more IGF-IRs than cells expressing wild-type p53. Neither wild-type p53 nor mutated p53 modulated the affinity of the IGF-IR.
Effects of wild-type and mutated p53 on IGF-I responsiveness
To investigate whether p53 modulates early steps in the IGF-I response, IGF-I-induced tyrosine phosphorylation of the IGF-IR and IRS-1 were studied. No detectable tyrosine phosphorylation of IGF-IR or IRS-1 was seen in starved cells. Stimulation with IGF-I (10 Ϫ8 m) for 1 min induced strong tyrosine phosphorylation of both the IGF-IR and IRS-1 ( Fig  4A) . IGF-I-induced tyrosine phosphorylation of the IGF-IR was decreased by wild-type p53 and increased by mutated p53 (wild-type p53: 42 Ϯ 14%, compared with cells that do not express p53 cultured at 30 C; mutated p53: 146 Ϯ 18% of control cells cultured at 37 C; Fig. 4, A and B) . Thus, cells expressing mutated p53 demonstrated 246% higher IGF-Iinduced tyrosine phosphorylation of IGF-IR, compared with cells expressing wild-type p53. Because we have shown that cells expressing mutated p53 express more IGF-IR protein than cells expressing wild-type p53, it is likely that the increase in IGF-I-induced tyrosine phosphorylation of the IGF-IR is primarily the result of increased numbers of IGF-IRs available for phosphorylation.
Wild-type p53 decreased IGF-I-induced tyrosine phosphorylation of IRS-1 by 26 Ϯ 3%, compared with control cells without p53 (Fig. 4, A and B) . No effect on IGF-I-induced tyrosine phosphorylation of IRS-1 was seen by mutated p53. Because the amount of IRS-1 protein was not regulated by wild-type p53 (data not shown), the reduced IGF-I-induced tyrosine phosphorylation of IRS-1 in cells expressing wildtype p53 was most likely the result of the reduction in IGF-IR expression and tyrosine phosphorylation.
Functional and physical interactions between Sp1 and p53 in the regulation of the IGF-IR promoter
Sp1 increases IGF-IR promoter activity in cells without endogenous Sp1 (Schneider cells) (18), whereas p53 decreases IGF-IR promoter activity in cells without endogenous p53 (Saos-2 cells) (26) . Because both Sp1 and p53 regulate IGF-IR promoter activity, a direct interaction between these two factors in this regulation was studied. The functional interaction between p53 and Sp1 was first studied in the osteogenic sarcoma-derived cell line, Saos-2. Sp1 and/or p53 p53 AND IGF-IRexpression vectors were transiently transfected into Saos-2 cells, together with the IGF-IR promoter fused to a luciferase reporter gene. Luciferase activity was measured after 48 h. p53 decreased promoter activity by 59% in the absence of Sp1 (Fig. 5A) . No effect on promoter activity was seen by Sp1 by itself. However, Sp1 counteracted the inhibitory effect of p53 on promoter activity in a dose-dependent manner (Fig. 5A ). This effect of Sp1 was not caused by inhibition of p53 expression, because p53 expression (as determined with immunoblotting) was not affected by Sp1 (Fig. 5B) . A functional interaction between p53 and Sp1 also was investigated in Schneider cells, which lack endogenous Sp1. Sp1 strongly increases IGF-IR promoter activity in these cells (Fig. 6A) . Wild-type p53 or mutated p53 was expressed in Schneider cells using transient transfection (Fig. 6B) . p53, by itself, did not regulate promoter activity in Schneider cells (Fig. 6A) . However, 60% of the Sp1-induced increase in IGF-IR promoter activity was counteracted by a maximum dose of p53 (Fig. 6A) . Surprisingly, both wild-type p53 and mutated p53 partially counteracted the Sp1-induced increase in promoter activity (Fig. 6A) . To test whether the functional interaction between p53 and Sp1 was caused by a physical interaction between these two factors, nuclear extracts of Saos-2 cells, transfected with Sp1 in the absence of p53 or in the presence of wild-type p53 or mutated p53, were immunoprecipitated with an Sp1-specific antiserum, followed by immunoblotting for p53. Wild-type and mutated p53 were coimmunoprecipitated with Sp1 (Fig. 5C) . Coimmunoprecipitation of p53 and Sp1 also was found in Schneider cells transfected with p53 and Sp1 (data not shown).
Discussion
Saos-2 osteosarcoma cells express a relatively high number of IGF-IRs, and one possible explanation for this high expression of IGF-IR could be that these cells lack p53. This is supported by the results, in the present study, that expression of wild-type p53 decreases IGF-IR expression in these cells. Furthermore, a recent study, published while this manuscript was in preparation, demonstrated that the IGF-IR is a physiologically relevant target of p53 in the process of apoptosis caused by Interleukin-3 withdrawal in hematopoietic cells. Similar to the present study, it was demonstrated that cells expressing mutated p53 expressed more Saos-2-DH4 cells, expressing a temperature-sensitive p53 under the control of a tetracycline-regulated system, were cultured for 5 days in the presence of tetracycline at 30 C (no p53, ⅷ), in the absence of tetracycline at 30 C (wild-type p53, ), in the presence of tetracycline at 37 C (no p53, f), or in the absence of tetracycline at 37 C (mutated p53, OE). Determination of IGF-I binding is described under Materials and Methods. B/F, bound/free. Each experiment was carried out in triplicate cultures. One representative experiment is shown in Fig 3. The experiment was repeated three times with similar results.
IGF-IR per cell than cells expressing wild-type p53 (12) . However, in that study, it was not possible to study the effect of expressing wild-type and mutated p53, compared with absent endogenous p53, because an inducible p53 expression was not used, and the parental cell line used expresses p53. Because the osteosarcoma cells used in the present study are null for p53, they provide a clean background for these types of studies. However, taken together, the results of both studies suggest that p53 regulates IGF-IR expression in two different types of cells of different origin, i.e. in erythroid cells of hematopoietic origin and in osteoblastic cells of mesenchymal origin, indicating that p53-induced regulation of IGF-IR expression may be a general mechanism. Although the overall effect of p53 on IGF-IR expression was relatively modest, the magnitude of change is sufficient to affect the function of cells and influence their responsiveness to growth factors. Thus, 3T3 cells with 15,000 IGF-IRs per cell are incapable of responding to IGF-I; a 50% increase in receptor number results in these cells being able to respond to IGF-I with maximal stimulation (33) . Furthermore, a 60 -70% reduction of the IGF-IR is sufficient to achieve reversal of a transformed phenotype (4); and, though down-regulation of the IGF-IR may have only small effects on the growth of tumor cells in vitro, this reduction in IGF-IR triggers a massive apoptotic response in vivo (10, 34) .
The effects of wild-type p53 and mutated p53 on IGF-Iinduced tyrosine phosphorylation of IGF-IR is explained, in part, by the finding that cells expressing mutated p53 express more IGF-IRs than cells expressing wild-type p53. The potential mechanism(s) for the difference in the magnitude of change between IGF-I-induced autophosphorylation of the IGFI-R and the expression of the IGFI-R protein, remains to be determined. In contrast, IRS-1 expression was not regulated by p53, and the reduction of IGF-I-induced tyrosine phosphorylation of IRS-1 seen in cells expressing wild-type p53 may be explained by the reduced number of activated IGF-IRs. Our results, showing that p53 regulates the numbers of IGF-IR and IGF-I-induced tyrosine phosphorylation of the IGF-IR and IRS-1, together with the results of Prisco et al. (12) , showing that p53 counteracts IGF-I inhibition of apoptosis, indicate that either wild-type p53 or IGF-IR antisense may be an effective treatment strategy for p53-negative osteogenic tumors expressing high levels of IGF-IRs.
p53 is not unique in regulating IGF-IR expression. The Wilms tumor supressor gene (WT1) also suppresses IGF-IR promoter activity (17, 35) , and overexpression of WT1 decreases the endogenous levels of IGF-IR and reduces IGF-Imediated cellular proliferation (36) .
Two other components of the IGF system, besides the IGF-IR, are regulated by p53. IGF-binding protein-3 (IGFBP-3) has been shown to be induced by p53 (37), whereas p53 AND IGF-IRpromoter activity of IGF-II is reduced by wild-type p53 (38) . IGFBP-3 is commonly an inhibitor of the mitogenic signaling by IGFs. Thus, p53 regulates the IGF system at the level of expression of one of its ligands (IGF-II), the bioavailability of ligands (IGFBP-3 expression), and at the expression of the IGF-IR. The fact that p53 induced regulation on all three levels of the IGF system was demonstrated using the Saos-2 osteosarcoma cells lacking p53.
In addition to the IGF-I receptor, two other genes, bcl-2 and MAP4, have been shown to be down-regulated by p53 (39, 40) . The functional role of MAP4 is not clear. Thus, the bcl-2 and the IGF-IR genes are the first genes shown to be downregulated by p53 and known to play a direct role in the process of cellular transformation. Interestingly, Sp1 has been shown to be a target for p53 in a erythroleukemia cell line (19) . In these cells, it was found that GM-CSF-inducible DNA-binding complexes contained both Sp1 and p53 and that these heterocomplexes bound both p53-and Sp1-binding sequences with high affinity. Immunoprecipitation of nuclear extracts indicated that Sp1 was associated, as a heterocomplex, with p53. The functional effect of such an interaction was, however, not investigated. p53 and Sp1 also interact and cooperate in tumor necrosis factor (TNF)-induced transcriptional activation of the HIV-1 Long-terminal repeat (41) . A physical interaction between p53 and Sp1 was seen after TNF stimulation. Our result, that Sp1 and p53 were coimmunoprecipitated in Saos-2 cells, supports the notion that Sp1 and p53 interact in a complex. Furthermore, in the present study, a functional interaction between Sp1 and wild-type p53, in the regulation of IGF-IR promoter activity, was found in Saos-2 cells. This is supported by our finding in Schneider cells that wild-type p53 counteract the stimulatory effect of Sp-1 on IGF-IR promoter activity. Surprisingly, in Schneider cells, the same effect was seen with mutated p53. The physiology of and mechanism behind this inhibitory effect of mutated p53 in Schneider cells remains to be elucidated. It has been suggested that Sp1 and p53 can form distinct associations that exhibit different DNA binding affinities, perhaps involving other nuclear proteins. Both Sp1 and p53 have the propensity to form large oligomeric structures in solution, with subsequent changes in their DNA Luciferase activity was measured after 48 h. Values are luciferase units normalized per total protein and are given as mean Ϯ SEM of duplicate cultures. The experiment was repeated twice with similar results. B, The effect of different doses of Sp1 expression vector (0 -500 ng) on the expression of p53, as determined using immunoblotting, for p53. Cultures were either transfected with a p53 expression vector (ϩ) or an empty expression vector (Ϫ). C, Physical interaction between p53 and Sp1 was determined, using nuclear extracts of Saos-2 cells transfected with Sp1 without p53 (Ϫ), or with p53 (ϩ, 0.3 g; ϩϩ, 0.6 g) or mutated p53 (M, 0.6 g). Extracts were immunoprecipitated with an Sp1 antiserum, followed by immunoblotting, for p53. binding activity (42, 43) . Heterocomplexes between Sp1 and p53 could exhibit selectivity in binding to Sp1 or p53 regulatory elements or a change in their trans-activating activity. The sequestering of Sp1 by p53 also could directly affect transcription from Sp1-regulated promoters. A precedent for such a regulatory mechanism has been reported for the tumor suppresser Rb, which was found to affect transcription of target genes through interactions with Sp1 (44). p53-induced stimulation of transcription is thought to occur when p53 binds to promoter sequences directly, whereas repression is thought to be via protein-protein interactions between p53 and other transcription factors. We are currently investigating the molecular mechanisms for the interaction between Sp1 and p53 in the regulation of the promoter activity of the IGF-IR.
In conclusion, p53 regulates IGF-IR expression and tyrosine phosphorylation of the IGF-IR and IRS-1 in an osteosarcoma cell-line. Furthermore, data indicating an interaction between p53 and Sp1 in the regulation of the promoter activity of IGF-IR are presented.
